{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:39:26Z","timestamp":1777113566207,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["113-2314-B-075-057 MY3"],"award-info":[{"award-number":["113-2314-B-075-057 MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2314-B-075-016 MY3"],"award-info":[{"award-number":["110-2314-B-075-016 MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113C-152"],"award-info":[{"award-number":["V113C-152"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114B-015"],"award-info":[{"award-number":["V114B-015"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114C-039"],"award-info":[{"award-number":["V114C-039"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016173","name":"Female Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tjog.2024.03.034","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:27:43Z","timestamp":1747074463000},"page":"413-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Endometrial cancer: Part II. Multimodality treatment of uterine high-grade serous carcinoma (clinical course I)"],"prefix":"10.1016","volume":"64","author":[{"given":"Che-Wei","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hsun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ling","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2024.03.034_bib1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.tjog.2022.09.001","article-title":"Endometrial cancer: Part I. Basic concept","volume":"61","author":"Wang","year":"2022","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3390\/cancers16051028","article-title":"Recent advances in endometrial cancer prevention, early diagnosis and treatment","volume":"16","author":"Rand","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tjog.2024.03.034_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ijgo.15578","article-title":"Asymptomatic endometrial cancer with Lynch syndrome; in a woman with primary infertility-A case report and literature review","volume":"167","author":"Noah","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ijgo.16138","article-title":"Use and knowledge of the two FIGO systems for nongestational abnormal uterine bleeding in the reproductive years: A multinational survey","volume":"168","author":"Ruiloba","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib5","unstructured":"Uterine Neoplasms. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) version 2.2025-Jan 31, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf [Assessed 21 February 2025]."},{"key":"10.1016\/j.tjog.2024.03.034_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib7","article-title":"Locally advanced and metastatic endometrial cancer: current and emerging therapies","volume":"129","author":"Salmom","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.tjog.2024.03.034_bib8","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1016\/S1470-2045(24)00192-X","article-title":"Participants of the 2023 gynecologic cancer InterGroup endometrial cancer consensus conference on clinical research. Clinical research in endometrial cancer: consensus recommendations from the gynecologic cancer InterGroup","volume":"25","author":"Creutzberg","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10333","key":"10.1016\/j.tjog.2024.03.034_bib9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2024.03.034_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.tjog.2024.03.034_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2024.02.002","article-title":"2023 FIGO staging system for endometrial cancer: the evolution of the revolution","volume":"184","author":"Gaffney","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/PGP.0000000000000898","article-title":"Targeted molecular testing in endometrial carcinoma: validation of a clinically driven selective ProMisE testing protocol","volume":"42","author":"Talhouk","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.tjog.2024.03.034_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tjog.2024.09.020","article-title":"FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients","volume":"64","author":"Wu","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.tjog.2023.09.013","article-title":"Integrating molecular pathology to endometrial cancer","volume":"62","author":"Li","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/JCMA.0000000000001101","article-title":"Primary surgical prevention of lymphedema","volume":"87","author":"Sun","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/JCMA.0000000000001088","article-title":"Supermicrosurgical lymphovenous anastomosis","volume":"87","author":"Lin","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/JCMA.0000000000001021","article-title":"Genital elephantiasis: surgical treatment and reconstruction","volume":"87","author":"Sun","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCMA.0000000000001016","article-title":"Lymphovenous shunts in the treatment of lymphedema","volume":"87","author":"Sun","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tjog.2024.11.004","article-title":"Lymphedema and sentinel lymph node mapping","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tjog.2024.04.008","article-title":"Lower limb lymphedema after surgical staging for endometrial cancer: current insights and future directions","volume":"63","author":"Cucinella","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.tjog.2024.05.003","article-title":"Sentinel-lymph-node mapping in endometrial cancer: tumor location matters?","volume":"63","author":"Liu","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.tjog.2023.11.011","article-title":"Precise lymph node biopsy for endometrial cancer confined to the uterus: analysis of 43 clinical cases","volume":"63","author":"Shi","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tjog.2023.07.037","article-title":"Para-aortic lymphadenectomy in endometrial cancer patients with left-sided inferior vena cava: a case report and literature review","volume":"63","author":"Higashi","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tjog.2024.11.006","article-title":"Current genetic test for ovarian cancer","volume":"64","author":"Yang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-24-01326","article-title":"First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial","volume":"43","author":"Marth","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tjog.2024.09.006","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): anti-HER2\/neu","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.tjog.2024.09.005","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tjog.2024.07.014","article-title":"Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer","volume":"63","author":"Chang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tjog.2024.08.001","article-title":"Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ijgo.15898","article-title":"Analysis of assisted reproductive outcomes in patients with atypical endometrial hyperplasia and early-stage endometrial cancer after fertility-sparing treatment","volume":"168","author":"Li","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.53604","article-title":"Surgical deescalation within gynecologic oncology","volume":"8","author":"Kanbergs","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tjog.2024.03.034_bib32","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.3802\/jgo.2024.35.e106","volume":"35","author":"Sakai","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ijgo.16146","article-title":"Impact of optimal secondary cytoreductive surgery on survival outcomes in women with recurrent endometrial carcinoma: a systematic review and meta-analysis","author":"Raffone","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib34","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e31","article-title":"Modified posterior pelvic exenteration combined with ileocecal resection for locally advanced endometrial cancer","volume":"36","author":"Kato","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2024.10.022","article-title":"Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"192","author":"Powell","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae101","article-title":"Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis","volume":"8","author":"Tjokrowidjaja","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.tjog.2024.03.034_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102701","article-title":"Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis","volume":"125","author":"Bartoletti","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.tjog.2024.03.034_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104555","article-title":"First-line treatments for advanced or recurrent endometrial cancer: systematic literature review of clinical evidence","volume":"206","author":"Mirza","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.tjog.2024.03.034_bib39","article-title":"Advanced endometrial cancer-The next generation of treatment: a society of gynecologic oncology journal club clinical commentary","volume":"55","author":"Tillmanns","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.tjog.2024.03.034_bib40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib41","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.03.034_bib42","article-title":"Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer","volume":"35","author":"Huo","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.annonc.2024.04.007","article-title":"Mito END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy","volume":"35","author":"Pignata","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(23)00016-5","article-title":"MITO investigators. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"24","author":"Pignata","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib47","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Study 309\u2013KEYNOTE-775 investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.03.034_bib49","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.3802\/jgo.2024.35.e40","article-title":"Analysis of East Asia subgroup in Study 309\/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer","volume":"35","author":"Yonemori","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib50","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2023.03.015","article-title":"Health-related quality of life in patients with advanced endometrial cancer treated with lenvatinib plus pembrolizumab or treatment of physician's choice","volume":"186","author":"Lorusso","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2024.03.034_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.10.008","article-title":"Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab","volume":"37","author":"Pawsey","year":"2025","journal-title":"Clin Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/IGC.0b013e31822e2991","article-title":"Re: the revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?","volume":"22","author":"Wen","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.03.034_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcma.2015.11.005","article-title":"Challenges in the management of recurrent endometrial cancer","volume":"79","author":"Wang","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib54","article-title":"Age did not affect the rate of subsequent hysterectomy following hysteroscopic surgery: a population-based retrospective cohort study from 2000 to 2020","volume":"15","author":"Huang","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tjog.2025.01.002","article-title":"Overcoming extensive abdominal adhesions: Utilizing mini-wound techniques for successful laparoscopic staging in cancer surgery","volume":"64","author":"Huang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"Suppl 2","key":"10.1016\/j.tjog.2024.03.034_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ijgo.14946","article-title":"Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO Systems 1 and 2","volume":"162","author":"Jain","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tjog.2024.12.001","article-title":"Transcervical resection of myoma (TCRM): Part II","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tjog.2024.11.002","article-title":"Transcervical resection of myoma (TCRM): Part I","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib59","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ijgo.15513","article-title":"Expression of netrin-1 in uterine serous carcinoma and its association with prognosis","volume":"166","author":"Ucuncu Kefeli","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.03.034_bib60","article-title":"Adjuvant therapy in early uterine serous carcinoma","volume":"16","author":"Garrett","year":"2025","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.tjog.2024.03.034_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2024.11.003","article-title":"Primary cytoreductive surgery for advanced epithelial ovarian cancer patients is still popular in gynecologic oncologists in Korea and Taiwan, particularly apparent in Taiwan","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib62","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.tjog.2024.09.002","article-title":"Neoadjuvant chemotherapy is associated with worse prognosis in patients with advanced-stage epithelial ovarian cancer: is it real?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tjog.2023.11.005","article-title":"Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JCMA.0000000000001069","article-title":"Minimally invasive approach is preferred for clinical stage 1 endometrioid-type endometrial cancer","volume":"87","author":"Wang","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib65","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tjog.2024.07.012","article-title":"Early removal of urinary catheter is an essential component of the enhanced recovery after surgery (ERAS) programs","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tjog.2024.04.004","article-title":"Adequate postoperative pain reduction is one of the critical components for enhanced recovery after surgery (ERAS)","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib67","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/JCMA.0000000000000982","article-title":"Early oral diet may enhance recovery from benign gynecologic surgery: a single center prospective study","volume":"86","author":"Yang","year":"2023","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib68","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.tjog.2024.09.001","article-title":"Minimally invasive surgery for endometrial cancer: the better choice?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib69","doi-asserted-by":"crossref","first-page":"109.e1","DOI":"10.1016\/j.ajog.2017.09.026","article-title":"Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG\/Gynecologic Oncology Group study","volume":"218","author":"Bishop","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/JCMA.0000000000001006","article-title":"Long-term outcome of minimally invasive staging surgery for clinical stage I endometrial cancer: a single institute experience in Taiwan","volume":"87","author":"Lu","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.03.034_bib71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.tjog.2024.03.019","article-title":"Prognostic factors and survival of endometrial cancer: an 11-year retrospective cohort study in Southern Taiwan","volume":"63","author":"Bing","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.03.034_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2014.02.010","article-title":"Impact of management on the prognosis of pure uterine papillary serous cancer\u2013A Taiwanese Gynecologic Oncology Group (TGOG) study","volume":"133","author":"Huang","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2024.02.002","article-title":"2023 FIGO staging system for endometrial cancer: the evolution of the revolution","volume":"184","author":"Gaffney","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib75","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cancers16101869","article-title":"Endometrial cancer: 2023 revised FIGO staging system and the role of imaging","volume":"16","author":"Santos","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tjog.2024.03.034_bib76","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3390\/cancers16061200","article-title":"Accuracy of frozen section biopsy in the diagnosis of endometrial cancer: a systematic review and meta-analysis","volume":"16","author":"Kopatsaris","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tjog.2024.03.034_bib77","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/cancers16183202","article-title":"Sentinel lymph node assessment in endometrial cancer: a review","volume":"16","author":"Clark","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tjog.2024.03.034_bib78","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3802\/jgo.2024.35.e29","article-title":"Sentinel node mapping in endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib79","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.tjog.2024.05.003","article-title":"Sentinel-lymph-node mapping in endometrial cancer: tumor location matters?","volume":"63","author":"Liu","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.03.034_bib80","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/jcm13051496","article-title":"The role of adjuvant therapy for the treatment of micrometastases in endometrial cancer: a systematic review and meta-analysis","volume":"13","author":"Ronsini","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.tjog.2024.03.034_bib81","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.3390\/cancers16213582","article-title":"Management of endometrial cancer: a comparative review of guidelines","volume":"16","author":"Kopatsaris","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tjog.2024.03.034_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1490347","article-title":"Paraaortic lymph node metastasis in endometrial cancer patients: a comprehensive analysis of rates, survival outcomes, and risk factors through systematic review and meta-analysis","volume":"14","author":"Han","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib83","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib84","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2024.03.034_bib85","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib86","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1158\/1078-0432.CCR-22-3861","article-title":"Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy","volume":"29","author":"Yagishita","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2024.03.034_bib87","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3802\/jgo.2025.36.e25","article-title":"Is presumed clinical stage I endometrial cancer using PET-CT and MRI accurate in predicting surgical staging?","volume":"36","author":"Seon","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib88","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.semnuclmed.2024.01.003","article-title":"Nuclear medicine and molecular imaging applications in gynecologic malignancies: a comprehensive review","volume":"54","author":"Khessib","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.tjog.2024.03.034_bib89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/gyno.2000.5738","article-title":"Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent primary serous peritoneal carcinoma: an initial report","volume":"77","author":"Wang","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib90","first-page":"775","article-title":"Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report","volume":"44","author":"Yuan","year":"1999","journal-title":"J Reprod Med"},{"key":"10.1016\/j.tjog.2024.03.034_bib91","first-page":"246","article-title":"Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas","volume":"29","author":"Sung","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MNM.0b013e32834ee824","article-title":"18F-Fluorodeoxyglucose positron emission tomography\/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities","volume":"33","author":"Salem","year":"2012","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.tjog.2024.03.034_bib93","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00259-005-1876-y","article-title":"18F-FDG PET in the management of endometrial cancer","volume":"33","author":"Chao","year":"2006","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.tjog.2024.03.034_bib94","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2019.12.039","article-title":"Second-line lenvatinib in patients with recurrent endometrial cancer","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib95","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CJI.0000000000000244","article-title":"Deep and durable response with combination CTLA-4 and PD-1 blockade in mismatch repair (MMR)-proficient endometrial cancer","volume":"42","author":"Oh","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.tjog.2024.03.034_bib96","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/cancers16020281","article-title":"Beyond PD(L)-1 blockade in microsatellite-instable cancers: current landscape of immune Co-inhibitory receptor targeting","volume":"16","author":"Crimini","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tjog.2024.03.034_bib97","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.03.034_bib98","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2024.03.034_bib99","unstructured":"Uterine Neoplasms. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) version 1.2025-Dec 16, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf [Assessed 21 January 2025]."},{"key":"10.1016\/j.tjog.2024.03.034_bib100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.tjog.2024.12.003","article-title":"Application of 2023 FIGO staging system for 2019 FIGO stage I endometrial cancer","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:23:00Z","timestamp":1762352580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455925000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1028455925000749"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2024.03.034","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endometrial cancer: Part II. Multimodality treatment of uterine high-grade serous carcinoma (clinical course I)","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2024.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}